Cadila Pharmaceuticals

Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.

History

In 1951 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation.

The Modi and Patel families decided to split the business in 1995, and two entities were formed: Cadila Pharmaceuticals Ltd (owned and controlled by Indravadan Modi and his son Rajiv Modi) and Cadila Healthcare (owned by Ramanbhai Patel and his son Pankaj Patel family).

In 2014, a cautionary notice appeared on the US Food and Drug Administration (FDA) website, highlighting substantial manufacturing practice discrepancies discovered by inspectors in March at Cadila Pharmaceuticals' Ankleshwar facility in Gujarat. This incident marked one among several Indian pharmaceutical companies receiving regulatory warnings from the FDA, indicating increased scrutiny on generic drugmakers. A similar kind of notices were again issued in 2016 and 2019.

In 2018, the chairman of the company, Rajiv Modi, went through a widely publicized and contentious divorce with his wife, Monica, who comes from a prominent Mumbai-based business family of Garware. At that time, Modi transferred to Monica, who relinquished her rights, while custody of their son was awarded to Modi.

In 2019, Cadila Pharmaceuticals formed a partnership with Norwegian start-up, Serca Pharmaceuticals to develop new treatment for heart patients.

In December 2023, Gujarat Police complied with a Gujarat High Court order, initiating a case against Rajiv Modi. The case involves accusations of rape, assault, and intentional insult by a Bulgarian woman employed as a flight attendant and personal assistant at the company. She reported multiple instances of sexual harassment from February to March 2023, stating that she was terminated in April 2023 after resisting Modi's alleged ''“illicit demands”''.

In November 2023, the company opened an active pharmaceutical ingredient (API) plant in Dahej, in Gujarat's Bharuch district. The facility was built with an investment of ₹200 crore, and is equipped with distributed control system (DCS) automation technology.

Operations

Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.

Research

Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 105,000 sq. ft. area at Dholka, Gujarat, India which is staffed by 300 scientists.

The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs.

Products and services

The Samba plant specializes in the production of a wide variety of drugs, totaling 140 types.
It was commissioned in September 2002, showcasing Cadila Pharmaceuticals' commitment to expanding its manufacturing capabilities.
With an expansive area of 11 acres, the plant represents a significant investment in pharmaceutical manufacturing infrastructure in the region.
The project type being derivative indicates a focus on producing pharmaceutical derivatives or derivative-based products.
The total budget for the project is 100 crores.The project was expected to be complete within around 800 days from the date of commencement.
Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – 'Rabeloc'. In 2009, the world's first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – 'Risorine' and world's first drug combination for prevention of Cardiovascular Diseases – 'Polycap' were introduced by Cadila Pharmaceuticals.
For the patients with Non Small Cell Lung Cancer (NSCLC), the company introduced 'Mycidac-C' - first in the class active immunotherapy as well as drug targeting Desmocollin.
Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D, Mycobutol and Sepsivac.

On 4 March 2024, Cadila Pharmaceuticals announced the launch of Cadiflu Tetra, a quadrivalent influenza vaccine approved for use in adults and children by the Drugs Controller General of India (DCGI), using proprietary technology with nano-sized particles to mimic the virus's external structure without containing its genetic material.

References

External links

* {{Official website, http://cadilapharma.com/

Pharmaceutical industry of Gujarat

Pharmaceutical companies of Gujarat
Companies based in Ahmedabad
Pharmaceutical companies established in 1951
Pharmaceutical companies of India
Indian brands
1951 establishments in Bombay State